Navigation Links
New oral angiogenesis inhibitor offers potential nontoxic therapy for a wide range of cancers
Date:7/1/2008

there is no good treatment.

"The success of TNP-470 in Phase I and II clinical trials opened up anti-angiogenesis as an entirely new modality of cancer therapy, along with conventional chemotherapy, radiotherapy and surgical approaches," says Ingber, now co-interim director of the Vascular Biology Program at Children's.

TNP-470 was first reformulated several years ago by Ronit Satchi-Fainaro, PhD, a postdoctoral fellow in Folkman's lab, who attached a large polymer to prevent it from crossing the blood-brain barrier (Cancer Cell, March 2005). That formulation, Caplostatin, has no neurotoxicity and is being developed for clinical trials. However, it must be given intravenously.

Benny took another approach, attaching two short polymers (PEG and PLA) to TNP-470. Experimenting with polymers of different lengths, she found a combination that formed stable, "pom-pom"-shaped nanoparticles known as polymeric micelles, with TNP-470 at the core. The polymers (both FDA-approved and widely used commercially) protect TNP-470 from the stomach's acidic environment, allowing it to be absorbed intact when taken orally. The micelles reach the tumor, react with water and break down, slowly releasing the drug.

Tested in mice, Lodamin had a significantly increased half-life, selectively accumulated in tumor tissue, blocked angiogenesis, and significantly inhibited primary tumor growth in mouse models of melanoma and lung cancer, with no apparent side effects when used at effective doses. Subsequent tests suggest that Lodamin retains TNP-470's unusually broad spectrum of activity. "I had never expected such a strong effect on these aggressive tumor models," Benny says.

Notably, Lodamin accumulated in the liver without causing toxicity, preventing liver metastases and prolonging survival. "This was one of the most surprising things I saw," says Benny. "When I looked at the livers of the mice, the treated group was almost clean. In the contro
'/>"/>

Contact: Bess Andrews
elizabeth.andrews@childrens.harvard.edu
617-919-3110
Children's Hospital Boston
Source:Eurekalert  

Page: 1 2 3

Related biology news :

1. Study finds blocking angiogenesis signaling from inside cell may lead to serious health problems
2. New inhibitor has potential as cancer drug
3. New research shows no link between aromatase inhibitors and cardiovascular problems
4. New partnership offers outsourced R&D in membrane biology
5. Census of protein architectures offers new view of history of life
6. NAS report offers new tools to assess health risks from chemicals
7. New class of drug offers hope to treatment-resistant AIDS patients
8. Darwin Symposium at Field Museum offers broad overview of his science and its impact
9. Conference on healthspan offers new opportunities for interdisciplinary collaboration
10. Protein controls blood vessel formation, offers new drug target
11. Genetic breakthrough offers promise in tackling kidney tumors
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New oral angiogenesis inhibitor offers potential nontoxic therapy for a wide range of cancers
(Date:9/18/2014)... invisible is probably the ultimate form of camouflage: you ... And this strategy is not as uncommon as you ... Baltimore County, USA, explains that the larval life stages ... one part of the anatomy that most creatures cannot ... eyes have to shield each individual eye unit with ...
(Date:9/17/2014)... UCLA atmospheric scientists were instrumental in the creation of ... tool to classify the fire threat potential of the ... a spark into an inferno. The index was introduced ... with UCLA and San Diego Gas and Electric. , ... to "extreme" that will be used to help fire ...
(Date:9/17/2014)... genetic disorder known as Jacobsen syndrome has been linked ... researchers at San Diego State University and the University ... treatment options for people with Jacobsen syndrome, the finding ... autism., Jacobsen syndrome affects approximately 1 in 100,000 people, ... in a person when there is a deletion at ...
Breaking Biology News(10 mins):Transparent larvae hide opaque eyes behind reflections 2UCLA scientists play key role in developing new Santa Ana Wildfire Threat Index 2A link between Jacobsen syndrome and autism 2
... is difficult to measure accurately each nation,s contribution of carbon ... the ground as coal, gas, and oil, and these fuels ... to generate the energy that is used to make products. ... countries where they are consumed. A team led by Carnegie,s ...
... The University of Texas at Austin whose technology developments in ... tens of thousands of patients with diseases such as cancer ... Institute of Medicine (IOM). Established in 1970, IOM is ... institute is considered one of the highest honors in health ...
... of spinal cord injury is receiving attention in the ... the department of biomedical engineering at NJIT, recently has ... micro-electrical stimulators for individuals with spinal cord injuries. ... year of support from a four-year, $1.4 million National ...
Cached Biology News:Links in the chain: Global carbon emissions and consumption 2UT professor elected to the Institute of Medicine of the National Academies 2UT professor elected to the Institute of Medicine of the National Academies 3NJIT researcher testing micro-electronic stimulators for spinal cord injuries 2
(Date:9/18/2014)... Sept. 18, 2014 Research and Markets ... Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market ... their offering. The global companion diagnostics ... 22.7% from 2014 to 2019. Factors such as rising ... of companion diagnostics by the pharmaceutical industry, support from ...
(Date:9/18/2014)... , Sept. 18, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ... previously announced concurrent but separate underwritten offerings of 10,000,000 ... the public of $2.00 per share, for expected gross ... Series A Convertible Preferred Stock at a price to ... proceeds of $20 million. Each share of Series A ...
(Date:9/18/2014)... Skeletal dysplasia is a group of rare diseases ... and cartilage. Its onset hits at the fetal ... mutation in the gene encoding fibroblast growth factor ... types of skeletal dysplasia, thanatophoric dysplasia (TD), a ... birth and is often lethal, and achondroplasia (ACH), ...
(Date:9/18/2014)... The quest for the ultimate memory device for computing ... at The City College of New York led by ... exhibit both magnetic and ferroelectric properties. , Combining both ... can occur between them and for the devices that ... Combining these two properties in a single material, however, ...
Breaking Biology Technology:Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 3Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3Researchers use iPS cells to show statin effects on diseased bone 2Researchers use iPS cells to show statin effects on diseased bone 3Oxides discovered by CCNY team could advance memory devices 2
... Amgen (Nasdaq: AMGN ) today announced that ... financial results on Monday, Jan. 24, 2011 after the close ... a conference call with the investment community at 2:00 p.m. ... Kevin Sharer, chairman and chief executive officer, and other members ...
... 2011 Sensus Healthcare is pleased to ... professional skin care products to be exclusively offered by ... Cases of skin cancer are on the rise and ... taking new aim at skin cancer (SM) in ...
... 2011 Cephalon, Inc., (Nasdaq: CEPH ) will hold ... founder and late Chairman and CEO on February 1, 2011, at ... Street, Philadelphia, Pennsylvania. Dr. Baldino founded Cephalon in ... one of the top ten biotechnology companies in the world. He ...
Cached Biology Technology:Amgen Announces Webcast of 2010 Fourth Quarter and Full Year Financial Results 2Sensus Healthcare Announces New Professional Skin Care Line - Sensus Skin Solutions™ 2Cephalon to Hold Public Memorial Service to Celebrate the Life of Company Founder, Frank Baldino, Jr., Ph.D. 2
Fas-ligand rabbit polyclonal antibody...
Mouse anti-JNK (PT183/185) Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
TRIAL SIZE Anti-Kaede [2F4] Monoclonal Research Focus: tag Storage: -20C Shipping Temperature: 4C...
AANAT [Arylalkylamine N-acetyltransferase; EC 2.3.1.87]...
Biology Products: